Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics develops investigational therapies for liver and viral diseases as a clinical-stage biotechnology company. Its news centers on programs for chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis, obesity, and coronavirus infections, including pevifoscorvir sodium, ALG-055009, ALG-097558, and ALG-170675.
Recurring updates cover clinical and nonclinical data, regulatory designations, scientific-conference presentations, quarterly financial results, research and development spending, licensing agreements, and equity compensation actions. Company releases also describe the Phase 2 B-SUPREME study of pevifoscorvir sodium, FDA Fast Track Designation for chronic HBV infection, and the exclusive license agreement for Greater China with Xiamen Amoytop Biotech.
Aligos Therapeutics (Nasdaq: ALGS) has initiated dosing in its Phase 2 B-SUPREME study of ALG-000184 for chronic hepatitis B virus (HBV) infection treatment. The study will evaluate 200 untreated subjects over 48 weeks, comparing ALG-000184 monotherapy to tenofovir disoproxil fumarate.
The randomized, double-blind study will assess both HBeAg+ and HBeAg- adult subjects, with primary endpoints focusing on HBV DNA levels. The trial will also evaluate safety, pharmacokinetics, and various biomarkers. Interim data is expected in 2026, with topline results anticipated in 2027.
Aligos Therapeutics (Nasdaq: ALGS) reported Q2 2025 progress and financial results, highlighting significant advancements in their liver and viral disease pipeline. The company's lead candidate, ALG-000184, is initiating Phase 2 B-SUPREME study for chronic HBV infection across multiple countries, with dosing expected to commence shortly. The Phase 1 study showed promising 96-week data with 100% of subjects achieving HBV DNA suppression.
The company reported positive Phase 2a HERALD data for ALG-055009, their MASH treatment candidate, demonstrating significant liver fat reduction and improvements in atherogenic lipids. Financial position remains strong with $122.9 million in cash as of June 30, 2025, providing runway into second half of 2026. Q2 2025 resulted in a net loss of $15.9 million, with R&D expenses at $14.0 million and G&A expenses at $5.6 million.
Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biotech company specializing in liver and viral disease therapies, has scheduled its Q2 2025 financial results announcement for Wednesday, August 6, 2025. The results will be released after U.S. financial markets close.
Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral disease therapies, has announced inducement grants for new employees. The Compensation Committee approved non-qualified stock options to purchase 2,100 shares on July 8, 2025.
The grants, made under Aligos' 2024 Inducement Plan, will vest over four years, with 25% vesting after the first year and the remainder vesting monthly. The exercise price equals the closing price of Aligos' common stock on the grant date. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are exclusively for new hires.
Aligos Therapeutics (NASDAQ: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral disease therapies, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management team will deliver a presentation on Thursday, June 5, 2025, at 2:00 PM ET. Interested parties can access the live webcast through the Presentation & Events section of Aligos' investor relations webpage. A replay will remain available for at least 30 days following the presentation.
Aligos Therapeutics (Nasdaq: ALGS) has appointed Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately. Kavanaugh brings over 25 years of experience in the biotechnology and pharmaceutical industries. She most recently served as Vice President, Corporate Law & Privacy Officer at Codexis. Her previous roles include being an independent legal consultant for companies like Genentech and Elan Pharmaceuticals, and serving as Practice Group Leader for BioOncology Development Law at Genentech.
The appointment was announced by Lesley Ann Calhoun, Executive Vice President, Chief Operating Officer, and Chief Financial Officer at Aligos, who emphasized Kavanaugh's extensive knowledge and broad expertise in legal matters. Kavanaugh holds a BA from UC Berkeley and a JD from Santa Clara University Law School.
Aligos Therapeutics (NASDAQ: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced an inducement grant for a newly hired employee. The grant, approved by the Company's Compensation Committee, consists of non-qualified stock options to purchase 26,000 shares of company stock.
The options were granted on May 13, 2025, with an exercise price equal to the closing price on the grant date. The shares will vest over 4 years, with 25% vesting after the first year and the remainder vesting monthly thereafter, contingent on continued employment. This grant was made under Aligos' 2024 Inducement Plan, specifically designed for equity awards to new hires, in compliance with Nasdaq Listing Rule 5635(c)(4).
Aligos Therapeutics (NASDAQ: ALGS) presented positive data from eight presentations at EASL Congress 2025, highlighting significant progress in their liver disease pipeline. The 96-week data for ALG-000184 showed remarkable results in chronic hepatitis B treatment, with 100% of subjects achieving HBV DNA viral suppression. In HBeAg+ subjects, 9/9 achieved HBV DNA suppression by Week 96, while all HBeAg- subjects (11/11) showed rapid decline and sustained suppression by Week 24.
Additionally, their THR-β agonist ALG-055009 demonstrated strong potential in MASH treatment, showing up to 46.2% placebo-adjusted median relative reductions in liver fat at Week 12. Notably, 11/14 subjects on stable GLP-1 agonists treated with ALG-055009 showed liver fat decreases, while maintaining a favorable tolerability profile with gastrointestinal-related adverse events similar to placebo.